savolitinib + cetuximab + FOLFOX

Savolitinib + cetuximab + FOLFOX is an investigational combination regimen being evaluated for the first-line treatment of RAS/BRAF wild-type metastatic colorectal cancer (mCRC). The regimen consists of **savolitinib** (Orpathys), a selective small-molecule inhibitor of the MET receptor tyrosine kinase; **cetuximab** (Erbitux), a monoclonal antibody targeting the epidermal growth factor receptor (EGFR); and **FOLFOX**, a standard chemotherapy backbone comprising oxaliplatin, leucovorin (folinic acid), and 5-fluorouracil. The rationale for this triplet combination is to simultaneously inhibit the MET and EGFR pathways, as MET amplification or activation is a recognized mechanism of resistance to anti-EGFR therapies like cetuximab in colorectal cancer. By co-targeting these pathways alongside cytotoxic chemotherapy, the regimen aims to improve objective response rates and survival outcomes in patients whose tumors may otherwise bypass EGFR inhibition through aberrant MET signaling.

Other names

savolitinib plus cetuximab and FOLFOX chemotherapy